What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Disease
- Cancer
His primary areas of study are Internal medicine, Rheumatoid arthritis, Arthritis, Surgery and Adverse effect.
Pharmacology is closely connected to Placebo in his research, which is encompassed under the umbrella topic of Internal medicine.
His Rheumatoid arthritis research is multidisciplinary, relying on both Methotrexate, Clinical trial, Intensive care medicine, Rheumatism and Physical therapy.
The concepts of his Physical therapy study are interwoven with issues in Alternative medicine, Evidence-based medicine, Severity of illness and Janus kinase inhibitor.
The various areas that Ronald F van Vollenhoven examines in his Arthritis study include Adalimumab and Pharmacotherapy.
His Surgery research incorporates themes from Gastroenterology and Infliximab.
His most cited work include:
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update (3425 citations)
- Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. (2280 citations)
- The PREMIER study: A multicenter, randomized, double‐blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment (1530 citations)
What are the main themes of his work throughout his whole career to date?
Ronald F van Vollenhoven mainly focuses on Internal medicine, Rheumatoid arthritis, Rheumatology, Surgery and Arthritis.
His Internal medicine study incorporates themes from Gastroenterology, Placebo and Immunology.
His Rheumatoid arthritis study combines topics from a wide range of disciplines, such as Adverse effect, Physical therapy, Clinical trial and Disease.
His Disease research focuses on subjects like Intensive care medicine, which are linked to Antirheumatic Agents.
His biological study spans a wide range of topics, including Rheumatism and Confidence interval.
He usually deals with Surgery and limits it to topics linked to Cohort and Cohort study.
He most often published in these fields:
- Internal medicine (76.07%)
- Rheumatoid arthritis (51.28%)
- Rheumatology (27.64%)
What were the highlights of his more recent work (between 2017-2021)?
- Internal medicine (76.07%)
- Rheumatoid arthritis (51.28%)
- Placebo (17.38%)
In recent papers he was focusing on the following fields of study:
His primary areas of investigation include Internal medicine, Rheumatoid arthritis, Placebo, Rheumatology and Clinical trial.
His Internal medicine study frequently links to adjacent areas such as Gastroenterology.
His Rheumatoid arthritis research includes elements of Randomized controlled trial, Abatacept and Arthritis.
His study in Placebo is interdisciplinary in nature, drawing from both Clinical endpoint, Adverse effect and Ustekinumab.
His Rheumatology research is multidisciplinary, incorporating elements of Frailty Index, Disease, Family medicine and Confidence interval.
His Clinical trial research integrates issues from Post-hoc analysis, Belimumab, Pediatrics and Intensive care medicine.
Between 2017 and 2021, his most popular works were:
- 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. (372 citations)
- Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study (128 citations)
- Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study (128 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Disease
- Cancer
Ronald F van Vollenhoven mostly deals with Internal medicine, Rheumatoid arthritis, Lupus erythematosus, Intensive care medicine and Adverse effect.
His Lupus nephritis, Systemic lupus erythematosus, Adalimumab, Methotrexate and Rheumatology investigations are all subjects of Internal medicine research.
His Rheumatoid arthritis study combines topics in areas such as Therapeutic strategy, Selection and Arthritis.
His work in Lupus erythematosus addresses subjects such as Young adult, which are connected to disciplines such as Cohort study, Lupus vasculitis, Severity of illness and Prospective cohort study.
The Intensive care medicine study combines topics in areas such as Standard care and Clinical trial.
His work is dedicated to discovering how Adverse effect, Placebo are connected with Ustekinumab, Upper respiratory tract infection and Janus kinase inhibitor and other disciplines.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
